Genta has announced its lead oncology product Genasense shows a high response rate when administered as an intravenous infusion for the treatment of advanced melanoma.

Preliminary results of a pilot study show a high objective response rate when Genasense is administered for the first time as a one-hour high-dose intravenous infusion, Genta said.

The study combined Genasense with temozolomide, the most commonly used anti-cancer drug for melanoma, and Abraxane.